Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metvix natural daylight PDT versus conventional red-light PDT for actinic keratosis
2013-000973-54Phase 3Completed
- Sponsor
- Galderma
- Start
- Apr 2013
- Modality
- Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Light/Condition-Responsive Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, single-blind trial of methyl aminolevulinate in actinic keratosis (AK) and hyperkeratosis (3 arms), sponsored by Galderma. Started Apr 2013; status: completed.
02
Drugs
methyl aminolevulinate
03
Conditions
actinic keratosis (AK)hyperkeratosis
Beyond the preview
Go deeper on 2013-000973-54.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2013-000973-54.